The role of the growth hormone/insulin-like growth factor system in visceral adiposity

Research output: Research - peer-reviewReview article

Abstract

There is substantial evidence that the growth hormone (GH)/insulin-like growth factor (IGF) system is involved in the pathophysiology of obesity. Both GH and IGF-I have direct effects on adipocyte proliferation and differentiation, and this system is involved in the cross-talk between adipose tissue, liver, and pituitary. Transgenic animal models have been of importance in identifying mechanisms underlying these interactions. It emerges that this system has key roles in visceral adiposity, and there is a rationale for targeting this system in the treatment of visceral obesity associated with GH deficiency, metabolic syndrome, and lipodystrophies. This evidence is reviewed, gaps in knowledge are highlighted, and recommendations are made for future research.
LanguageEnglish
Pages1-10
JournalBiochemistry Insights
Volume10
DOIs
StatePublished - 20 Apr 2017

Fingerprint

Adiposity
Somatomedins
Growth Hormone
Lipodystrophy
Genetically Modified Animals
Abdominal Obesity
Insulin-Like Growth Factor I
Adipocytes
Adipose Tissue
Animal Models
Obesity
Liver
Therapeutics

Cite this

@article{5499c9f109124606a80f15bdee711f09,
title = "The role of the growth hormone/insulin-like growth factor system in visceral adiposity",
abstract = "There is substantial evidence that the growth hormone (GH)/insulin-like growth factor (IGF) system is involved in the pathophysiology of obesity. Both GH and IGF-I have direct effects on adipocyte proliferation and differentiation, and this system is involved in the cross-talk between adipose tissue, liver, and pituitary. Transgenic animal models have been of importance in identifying mechanisms underlying these interactions. It emerges that this system has key roles in visceral adiposity, and there is a rationale for targeting this system in the treatment of visceral obesity associated with GH deficiency, metabolic syndrome, and lipodystrophies. This evidence is reviewed, gaps in knowledge are highlighted, and recommendations are made for future research.",
author = "Moira Lewitt",
year = "2017",
month = "4",
doi = "10.1177/1178626417703995",
volume = "10",
pages = "1--10",
journal = "Biochemistry Insights",
issn = "1178-6264",
publisher = "sage",

}

The role of the growth hormone/insulin-like growth factor system in visceral adiposity. / Lewitt, Moira.

In: Biochemistry Insights, Vol. 10, 20.04.2017, p. 1-10.

Research output: Research - peer-reviewReview article

TY - JOUR

T1 - The role of the growth hormone/insulin-like growth factor system in visceral adiposity

AU - Lewitt,Moira

PY - 2017/4/20

Y1 - 2017/4/20

N2 - There is substantial evidence that the growth hormone (GH)/insulin-like growth factor (IGF) system is involved in the pathophysiology of obesity. Both GH and IGF-I have direct effects on adipocyte proliferation and differentiation, and this system is involved in the cross-talk between adipose tissue, liver, and pituitary. Transgenic animal models have been of importance in identifying mechanisms underlying these interactions. It emerges that this system has key roles in visceral adiposity, and there is a rationale for targeting this system in the treatment of visceral obesity associated with GH deficiency, metabolic syndrome, and lipodystrophies. This evidence is reviewed, gaps in knowledge are highlighted, and recommendations are made for future research.

AB - There is substantial evidence that the growth hormone (GH)/insulin-like growth factor (IGF) system is involved in the pathophysiology of obesity. Both GH and IGF-I have direct effects on adipocyte proliferation and differentiation, and this system is involved in the cross-talk between adipose tissue, liver, and pituitary. Transgenic animal models have been of importance in identifying mechanisms underlying these interactions. It emerges that this system has key roles in visceral adiposity, and there is a rationale for targeting this system in the treatment of visceral obesity associated with GH deficiency, metabolic syndrome, and lipodystrophies. This evidence is reviewed, gaps in knowledge are highlighted, and recommendations are made for future research.

U2 - 10.1177/1178626417703995

DO - 10.1177/1178626417703995

M3 - Review article

VL - 10

SP - 1

EP - 10

JO - Biochemistry Insights

T2 - Biochemistry Insights

JF - Biochemistry Insights

SN - 1178-6264

ER -